<i>Helicobacter pylori</i> and Epstein-Barr Virus Co-Infection in Polish Patients with Gastric Cancer – A Pilot Study

Dzikowiec, Magdalena; Lik, Przemysław; Kiszałkiewicz, Justyna; Kuczyńska, Aleksandra; Mordalski, Marek; Nejc, Dariusz; Piekarski, Janusz; Brzeziańska-Lasota, Ewa; Pastuszak-Lewandoska, Dorota

doi:10.33073/pjm-2022-004

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After full-text reading, we eliminated 3 papers because the authors did not disclose a statistical analysis or raw data supportive of significant or nonsignificant associations. 19 – 21 Two studies 22 , 23 were excluded because they duplicated patients reported in the subsequent publication by Varga et al , 24 ending up with 16 different articles from 12 different research teams for this review ( Figure 1 , Table 1 ). Overall the studies included 9735 individuals sorted in the following groups: 215 EBVaGC, 302 EBVnGC, 2571 GC of unknown EBV status, 814 noncancerous gastric diseases (AG/IM/Dys), and 5833 controls (820 NAG, 93 with nonspecified dyspeptic symptoms and 4920 healthy blood donors).…”

Section: Resultsmentioning

confidence: 99%

“…After full-text reading, we eliminated 3 papers because the authors did not disclose a statistical analysis or raw data supportive of significant or nonsignificant associations. [19][20][21] Two studies 22,23 were excluded because they duplicated patients reported in the subsequent publication by Varga et al, 24 ending up with 16 different articles from 12 different research teams for this review (Figure 1, Table 1). Overall the studies included 9735 For a better understanding and management of the data, we grouped the selected studies into 2 categories: (i) studies comparing patients with gastric tumors of known EBV status (Figure 2), and (ii) studies comparing patients with GC or gastric lesions of unknown EBV status (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Antibodies Against Epstein–Barr Virus as Disease Markers of Gastric Cancer: A Systematic Review

Fontes-Lemus

Zhao

Rabkin

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Introduction: Gastric cancer is the fourth deadliest cancer worldwide. Due to the lack of specific early symptoms and noninvasive methods for early detection, the prognosis of gastric cancer patients is poor. Gastric cancer has a well-recognized infectious etiology, with Helicobacter pylori and Epstein–Barr Virus being the main associated infectious agents. Although other Epstein–Barr Virus-associated malignancies often manifest with abnormal levels of anti-Epstein–Barr Virus antibodies, it is not clear whether this is also true for gastric cancer. Potentially, these antibodies could serve as a noninvasive tool for gastric cancer screening or as markers for gastric cancer risk and provide a better understanding of the participation of Epstein–Barr Virus in the development of this neoplasm. Methods: We conducted a systematic review of articles analyzing anti-Epstein–Barr Virus serology in gastric cancer and precursor lesions following PRISMA guidelines. Patients were classified according to the Correa cascade of gastric lesions and whether they were positive or negative by EBER- in situ hybridization (Epstein–Barr Virus-associated gastric cancer and Epstein–Barr Virus-nonassociated gastric cancer, respectively). Results: We retrieved 16 articles involving 9735 subjects from 12 different countries and 4 databases, PubMed, SciELO, Scopus, and Google Scholar. Higher antibody titers were observed not only in Epstein–Barr Virus-associated gastric cancer than in Epstein–Barr Virus-nonassociated gastric cancer but also in Epstein–Barr Virus-nonassociated gastric cancer and gastric cancer–precursor lesions when compared with patients with mild dyspepsia or healthy controls. In all cases, the associations were predominantly with antibodies directed against lytic cycle antigens. Conclusion: Data support the role of Epstein–Barr Virus lytic reactivation in the development of advanced gastric lesions. However, more studies are needed to confirm these associations, particularly the association with lesions considered negative by EBER- in situ hybridization, and to establish a set of antibodies and thresholds indicative of enhanced risk to develop these lesions.

show abstract

Section: Resultsmentioning

confidence: 99%

“…After full-text reading, we eliminated 3 papers because the authors did not disclose a statistical analysis or raw data supportive of significant or nonsignificant associations. [19][20][21] Two studies 22,23 were excluded because they duplicated patients reported in the subsequent publication by Varga et al, 24 ending up with 16 different articles from 12 different research teams for this review (Figure 1, Table 1). Overall the studies included 9735 For a better understanding and management of the data, we grouped the selected studies into 2 categories: (i) studies comparing patients with gastric tumors of known EBV status (Figure 2), and (ii) studies comparing patients with GC or gastric lesions of unknown EBV status (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

Antibodies Against Epstein–Barr Virus as Disease Markers of Gastric Cancer: A Systematic Review

Fontes-Lemus

Zhao

Rabkin

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Analysis of Spermine Oxidase gene and proinflammatory cytokines expression in gastric cancer patients with and without Helicobacter pylori infection – A pilot study in Polish population

Dzikowiec,

Galant,

Lik

et al. 2024

Advances in Medical Sciences

View full text Add to dashboard Cite

Epstein-Barr Virus and <i>Helicobacter pylori</i> as Two Main Risk Factors in Gastric Cancer

Zeynali,

Teimouri,

Hashemi

et al. 2024

OBM Genet

View full text Add to dashboard Cite

Microbial and viral pathogens have emerged as pivotal agents in oncogenesis. Research conducted in the last twenty years has significantly enhanced our comprehension of the cancer-causing capabilities of infectious agents. An illustrative instance is gastric cancer (GC), which is closely associated with Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) infections. Despite concerted endeavors, GC remains a serious clinical challenge ranking as the fifth most commonly diagnosed cancer worldwide. In 2020, an estimated 768,793 people died from GC in the world. The pathogenicity island (PAI), cagA protein, VacA and other virulence factors in H. pylori and several latency factors such as EBNA-1, LMP-1 and LMP2A in Epstein-Barr virus as well as pattern of gene methylation and EBV and H. pylori co-infection are shown as the main causes of pathogen-related GC. The unique molecular and clinical characteristics associated with EBV and H. pylori in GC, highlight the importance of further understanding their respective roles in GC development and progression. This knowledge may inform future preventive and therapeutic strategies targeting these infectious agents in the context of GC. This review aims to elucidate the mechanisms underpinning EBV and H. pylori-induced carcinogenesis in GC.

show abstract

Helicobacter pylori and Epstein-Barr Virus Co-Infection in Polish Patients with Gastric Cancer – A Pilot Study

Cited by 3 publications

References 31 publications

Antibodies Against Epstein–Barr Virus as Disease Markers of Gastric Cancer: A Systematic Review

Antibodies Against Epstein–Barr Virus as Disease Markers of Gastric Cancer: A Systematic Review

Analysis of Spermine Oxidase gene and proinflammatory cytokines expression in gastric cancer patients with and without Helicobacter pylori infection – A pilot study in Polish population

Epstein-Barr Virus and <i>Helicobacter pylori</i> as Two Main Risk Factors in Gastric Cancer

Contact Info

Product

Resources

About